Core Viewpoint - The article highlights the recent developments of BGI Biotechnology (博安生物), including a significant shareholder transfer and the approval of its biosimilar drug BA6101 in Bolivia [1]. Group 1: Shareholder Activity - On January 13, BGI Biotechnology's shareholders transferred stocks from China Securities Registration and Clearing Hong Kong to CITIC Securities Brokerage Hong Kong, with a market value of HKD 512 million, accounting for 8.76% of the total shares [1]. Group 2: Product Approval - On January 13, BGI Biotechnology announced that its self-developed drug BA6101 (60mg) has been approved for market release by Bolivia's National Medicines and Health Technologies Agency (AGEMED) [1]. - BA6101 is a biosimilar referencing the original drug Prolia®, which is widely used globally for the treatment of osteoporosis [1].